Macitentan for the treatment of pulmonary arterial hypertension

References

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25):D34-41
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12):13S-24S
   Web of Science ®Google Scholar
• Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21(126):321-7
   PubMedGoogle Scholar
• Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-17
   PubMed Web of Science ®Google Scholar
• Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), and International Society of Heart and Lung Transplantation (ISHLT). Galie N, Hoepper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-63
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
   PubMed Web of Science ®Google Scholar
• Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165(3):398-405
   PubMed Web of Science ®Google Scholar
• Dupuis J, Hoepper M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31(2):407-15
   PubMed Web of Science ®Google Scholar
• Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33(2):753-8
   PubMed Web of Science ®Google Scholar
• Sauvageau S, Thorin E, Caron A, Dupuis J. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood) 2006;231(6):840-6
   PubMed Web of Science ®Google Scholar
• Sauvageau S, Thorin E, Caron A, Dupuis J. Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007;44:375-81
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-19
   PubMed Web of Science ®Google Scholar
• Galiè N, Rubin LJ, Hoepper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093-100
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014;172(2):332-9
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34:770-1
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31
   PubMed Web of Science ®Google Scholar
• Comellas AP, Briva A, Dada LA, et al. Endothelin-1 impairs alveolar epithelial function via endothelial ETB receptor. Am J Resp Crit Care Med 2009;179(2):113-22
   PubMed Web of Science ®Google Scholar
• Bolli MH, Boss C, Binkert C, et al. The discovery of a N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent, dual endothelin receptor antagonist. J Med Chem 2012;55(17):7849-61
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014;13(3):391-405
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
   PubMed Web of Science ®Google Scholar
• Gatfield J, Grandjean CM, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor anatagonists in pulmonary arterial smooth muscle cells. PLoS One 2012;7(10):1-11
   Web of Science ®Google Scholar
• Iglarz M, Bossu A, Wanner D. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sidharta PN, Giersbergen P, Halabi P, Dingemanse J. Macitentan: entry into humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011;67:977-84
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PL, Dingemanse J. Safety, tolerability, pharmacokinetics and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple dose study in healthy subjects. J Clin Pharmacol 2013;53(11):1131-8
   PubMed Web of Science ®Google Scholar
• Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 2013;52(8):685-92
   PubMed Web of Science ®Google Scholar
• Bruderer S, Hopfgartner GR, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 2012;42(9):901-10
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013;42(6):1622-32
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18
   PubMed Web of Science ®Google Scholar
• Patel T, McKeage K. Macitentan: first Global Approval. Drugs 2014;74:127-33
   PubMed Web of Science ®Google Scholar
• Thompson CA. Macitentan approved by FDA to delay progression of PAH. Am J Health-Syst Pharm 2013;70:2054
   PubMed Web of Science ®Google Scholar
• Weiss J, Theile D, Ruppell MA, et al. Interaction profile of macitentan, a new non-selective sendothelin-1 receptor antagonist, in vitro. Eur J Pharmacol 2013;701(1-3):168-75
   PubMed Web of Science ®Google Scholar
• Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue targeting dual endothelin receptor antagonist. AAPS J 2012;14(1):68-78
   PubMed Web of Science ®Google Scholar
• Sidharta PN, Lindegger N, Ulc I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with renal or hepatic impairment. J Clin Pharmacol 2014;54(3):291-300
   PubMed Web of Science ®Google Scholar
• Sidharta PN, van Giersbergen PL, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects. Am J Respir Crit Care Med 2012;185:A4802
   Google Scholar
• Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin healthy male subjects. Br J Clin Pharmacol 2009;68:788-9
   Web of Science ®Google Scholar